BV6 enhances apoptosis in Lung cancer cells by ameliorating caspase expressions through attenuation of XIAP, cIAP‑1, and cIAP‑2 proteins

Abstract

Objective: The present study aimed to investigate the inhibitory role of second mitochondria determined activator of caspases mimetic on inhibitor of apoptosis proteins (IAPs) and regulation of caspases in nonsmall cell lung cancer cell line. Materials and Methods: Dimethyl sulfoxide and 3‑(4, 5‑dimethyl thizol‑2‑yl)‑2, 5‑diphenyl tetrazolium bromide (MTT) assay was done to determine the IC50 of BV6 using NCI‑H23 cell line. The levels of mRNA of X‑linked IAP (XIAP), cellular IAP (cIAP‑1), cIAP‑2, caspase‑6, and caspase‑7 in H23 cell line were evaluated by a quantitative real‑time polymerase chain reaction, while their protein expressions were tested using western blotting. Results: Two doses of BV6 dependently downregulated the expression of mRNA of XIAP (P = 0.002, P= 0.0003 vs. untreated), cIAP‑1 (P = 0.05, P = 0.005 vs. untreated), and cIAP‑2 (P = 0.001, P = 0.0002 vs. untreated), respectively, while the compound upregulated the mRNA expression of caspase‑6 (P = 0.001, P < 0.0001 vs. untreated) and caspase‑7 (P = 0.001, P = 0.0004 vs. untreated), respectively. Dose dependent of BV6 treatment significantly decreased the protein level of XIAP (P = 0.003, P = 0.007 vs. untreated), cIAP‑1 (P = 0.02, P = 0.01 vs. untreated), and cIAP‑2 (P = 0.008,P = 0.008 vs. untreated), respectively. However, the compound increased the protein level of caspase‑6 and caspase‑7 when compared to untreated control (P = 0.006,P = 0.001) and (P = 0.01, P = 0.001), respectively. Conclusions: The result showed that BV6 treatment reduced the level of mRNA of XIAP, cIAP‑1, and cIAP‑2 and increased the gene expression of caspase‑6 and caspase‑7 in NCI‑H23 cell line. Therefore, the study revealed that BV6 could be used in future as additional therapeutics in lung cancer.